• Follow the Money: Blackstone Launches Portfolio Company, PCORI Approves Funds for CER Studies, Funds Gifted for Alzheimer’s Research, More

    Clinical Research News | Blackstone launches the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation; the Patient-Centered Outcomes Research Institute secures approval of funding awards to support new patient-centered comparative clinical effectiveness research studies; Laurence Belfer gifts funds to the University of Texas MD Anderson Cancer Center to strengthen neurodegeneration research through the Belfer Neurodegeneration Consortium, a transformative multi-institutional initiative to advance the study and treatment of Alzheimer’s disease; more.

    May 28, 2024

  • The Risk-Based Data Management (RBDM) Revolution

    Clinical Research News | The clinical trials landscape is evolving with more data, increased investment in personalized medicines and a shift toward decentralized and hybrid clinical trials. At the same time, the industry is attempting to become more efficient and harness new technologies and data science in operations.

    May 24, 2024

  • Pan-RAS Inhibitor Offers Hope of Improved Pancreatic Cancer Prognosis

    Clinical Research News | A consortium of pancreatic cancer researchers sharing information in real time has shown that an oral pan-RAS inhibitor known as RMC-7977, developed by Revolution Medicines, effectively targets the common cancer-causing RAS proteins while minimally impacting normal cells—and did so across a comprehensive range of preclinical models in a series of similar experiments.

    May 22, 2024

  • Brain Stimulation Device Could Make Precision Mental Health A Reality

    Clinical Research News | In the not-too-distant future, disorders of the brain could be treated with the same precision as heart disease and cancer. The means will be a therapeutic brain-computer interface (BCI) the size of a small blueberry for people suffering from treatment-resistant depression that uses a similar type of implant technology as Elon Musk’s Neuralink for helping paralyzed people speak.

    May 21, 2024